97.01

5.71% 5.1322

Blueprint Medicines Corp (BPMC)

Overview News Price History Option Chain Financials Why BPMC Down? Discussions Forecast

Blueprint Medicines Corp stock is traded at $97.01, with a volume of 471.20K. It is up +5.71% in the last 24 hours and up +9.61% over the past month. Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Previous Close:

$91.88

Open:

$91

24h Volume:

471.20K

Relative Volume:

0.77

Market Cap:

$5.95B

Revenue:

$362.80M

Net Income/Loss:

$-205.49M

P/E Ratio:

-10.56

EPS:

-9.19

Net Cash Flow:

$-347.59M

1W Performance:

+16.46%

1M Performance:

+9.61%

6M Performance:

-9.39%

1Y Performance:

+62.50%

1-Day Range:

$91.00

$97.24

1-Week Range:

$87.28

$97.19

52-Week Range:

$56.74

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name

Blueprint Medicines Corp

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-374-7580

Address

45 SIDNEY STREET, CAMBRIDGE, MA

Employee

655

Twitter

@BlueprintMeds

Next Earnings Date

2024-10-30

Latest SEC Filings

BPMC's Discussions on Twitter

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform
Aug-21-23	Reiterated	Needham	Buy
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Needham	Buy
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy
Jul-08-22	Initiated	Oppenheimer	Outperform
Jun-27-22	Initiated	Wells Fargo	Underweight
Jun-10-22	Downgrade	Citigroup	Neutral → Sell
Jun-01-22	Upgrade	Jefferies	Hold → Buy
Mar-01-22	Initiated	Citigroup	Neutral
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jan-25-22	Upgrade	Stifel	Hold → Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Sep-30-21	Resumed	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Hold
Nov-02-20	Reiterated	H.C. Wainwright	Buy
Nov-02-20	Downgrade	Jefferies	Buy → Hold
Oct-30-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-15-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Equal Weight
Mar-17-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Nov-06-19	Upgrade	Raymond James	Outperform → Strong Buy
Oct-22-19	Initiated	JMP Securities	Mkt Outperform
Oct-03-19	Initiated	H.C. Wainwright	Buy
Sep-12-19	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-29-19	Initiated	Piper Jaffray	Neutral
Aug-15-19	Resumed	Raymond James	Mkt Perform
Jul-18-19	Initiated	Deutsche Bank	Buy
May-23-19	Resumed	Goldman	Buy
Apr-03-19	Initiated	Morgan Stanley	Overweight
Sep-25-18	Initiated	Leerink Partners	Outperform
Dec-11-17	Reiterated	Goldman	Buy

View All

Blueprint Medicines Corp Stock (BPMC) Latest News

Nov 04, 2024

Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve

Nov 04, 2024

Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 01, 2024

Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat

Nov 01, 2024

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Yahoo Finance

Oct 30, 2024

Oct 28, 2024

When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St

Oct 28, 2024

Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 28, 2024

Oct 27, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance

Oct 27, 2024

Oct 26, 2024

UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World

Oct 26, 2024

Oct 25, 2024

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart

Oct 25, 2024

Oct 24, 2024

Analyst Ratings For Blueprint Medicines - Benzinga

Oct 24, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 23, 2024

Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales - Investing.com

Oct 23, 2024

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 23, 2024

Blueprint Medicines (BPMC) Scheduled to Post Earnings on Wednesday - MarketBeat

Oct 23, 2024

Oct 22, 2024

SG Americas Securities LLC Has $233,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 22, 2024

Oct 21, 2024

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Oct 21, 2024

Oct 16, 2024

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Financial Times

Oct 16, 2024

Oct 15, 2024

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know - Yahoo Finance

Oct 15, 2024

Oct 11, 2024

Blueprint Medicines Corp [NASDAQ: BPMC] Sees Decrease in Stock Value - Knox Daily

Oct 11, 2024

Activin Receptor Type 1 Market Review: All Eyes on 2024 Outlook - IndiaPolitics.com

Oct 11, 2024

The Blueprint Medicines Corp (BPMC) had a good session last reading, didn’t it? - US Post News

Oct 11, 2024

Brokers Issue Forecasts for Blueprint Medicines Co.'s Q2 2026 Earnings (NASDAQ:BPMC) - MarketBeat

Oct 11, 2024

Dimensional Fund Advisors LP Sells 16,619 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 11, 2024

Oct 08, 2024